BCLI BRAINSTORM CELL THERAPEUTICS INC US FDA Inspections 8-K Filing 2023 - FDA Review of ALS Stem Cell Therapy Brainstorm Cell Therapeutics Inc. announced that the FDA will review the Biologics License Application for its stem cell therapy for ALS, with a target action date of December 8, 2023.Get access to all SEC 8-K filings of the BRAINSTORM CELL THERAPEUTICS INC